Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team

TitleAndrogen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team
Publication TypeMiscellaneous
Year of Publication2014
AuthorsSmall, EJay, Youngren, J, Thomas, G, Olson, S, Toschi, A, Foye, A, Alumkal, JJ, Rettig, M, Gleave, MEdwin, Evans, CP, ,